Wordt geladen...
Prostate-Specific Antigen Velocity Risk Count Improves the Specificity of Screening for Clinically Significant Prostate Cancer
OBJECTIVE: Prostate-specific antigen (PSA)-based prostate cancer (CaP) screening has been shown to reduce CaP mortality at the expense of detecting some tumors that might never cause symptoms. PSA velocity (PSAV) has been shown to predict cancer-specific mortality after treatment. Our objective was...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3338148/ https://ncbi.nlm.nih.gov/pubmed/22296334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2011.10900.x |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|